Indication for antithrombotic therapy for atrial fibrillation: Reconciling the guidelines with clinical practice

European Heart Journal, Supplement

Volumn 7, Issue C, 2005, Pages

  Emmerich, Joseph ^a   Le Heuzey, Jean Yves ^b   Bath, Philip M W ^c   Connolly, Stuart J ^d  

^a INSERM   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Atrial fibrillation; Coagulation; Stroke; Treatment guidelines; Vitamin K antagonists; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CLINICAL PRACTICE; EMBOLISM; EVIDENCE BASED MEDICINE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; STROKE;

EID: 18744388305     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui017     Document Type: Review

References (51)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22:983-988.
2. Albers GW, Dalen JE, Laupacis A et al. Antithrombotic therapy in atrial fibrillation. Chest 2001;119(Suppl. 1):194S-206S.
3. Krahn AD, Manfreda J, Tate RB et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-484.
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987;147:1561-1564.
5. Rockson SG, Albers GW. Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. J Am Coll Cardiol 2004;43:929-935.
6. Lin HJ, Wolf PA, Kelly-Hayes M et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996;27:1760-1764.
7. Jorgensen HS, Nakayama H, Reith J et al. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke 1996;27: 1765-1769.
8. Lamassa M, Di Carlo A, Pracucci G et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 2001;32:392-398.
9. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375.
10. Ezekowitz MD. Atrial fibrillation: the epidemic of the new millennium. Ann Intern Med 1999;131:537-538.
11. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
12. Hart RG, Benavente O, McBride R et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
13. Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J 2001;22:1852-1923.
14. Singer DE, Albers GW, Dalen JE et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl. 3):429S-456S.
15. Thomson R, Parkin D, Eccles M et al. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet 2000;355:956-962.
16. Snow V, Weiss KB, LeFevre M et al. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2003;139:1009-1017.
17. Connolly SJ. Anticoagulation for patients with atrial fibrillation and risk factors for stroke. Warfarin reduces the risk by two thirds, but doctors still aren't prescribing it enough. BMJ 2000;320:1219-1220.
18. York M, Agarwal A, Ezekowitz M. Physicians' attitudes and the use of oral anticoagulants: surveying the present and envisioning future. J Thromb Thrombolysis 2003;16:33-37.
19. Dubhghaill CT, Moonen L, O'Loughlin A et al. Implementation of anticoagulation guidelines in general practice: a practice report. Ir Med J 2003;96:296-299.
20. Hart RG, Palacio S, Pearce LA. Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials. Stroke 2002;33:2722-2727.
21. Hack W, Kaste M, Bogousslavsky J et al. European Stroke Initiative Recommendations for Stroke Management-update 2003. Cerebrovasc Dis 2003;16:311-337.
22. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-1511.
23. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-1262.
24. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-691.
25. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348:633-688.
26. Petersen P, Boysen G, Godtfredsen J et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;1:175-179.
27. Pengo V, Zasso A, Barbero F et al. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. Am J Cardiol 1998;82:433-437.
28. Gullov AL, Koefoed BG, Petersen P et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998;158:1513-1521.
29. Morocutti C, Amabile G, Fattapposta F et al. Indobufen versus warfarin in the secondary prevention of major vascular events in non-rheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke 1997;28:1015-1021.
30. Harenberg J, Weuster B, Pfitzer M et al. Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin. Semin Thromb Hemost 1993;19(Suppl. 1):116-121.
31. Ezekowitz MD, Bridgers SL, James KE et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992;327:1406-1412.
32. Connolly SJ, Laupacis A, Gent M et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-355.
33. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991;84:527-539.
34. Hellemons BS, Langenberg M, Lodder J et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ 1999;319:958-964.
35. Posada IS, Barriales V. Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. Am Heart J 1999;138:137-143.
36. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke 2000;31:817-821.
37. Hylek EM, Skates SJ, Sheehan MA et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-546.
38. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-2870.
39. Thomson R, McElroy H, Sudlow M. Guidelines on anticoagulant treatment in atrial fibrillation in Great Britain: variation in content and implications for treatment. BMJ 1998;316:509-513.
40. Lip GY, Golding DJ, Nazir M et al. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract 1997;47:285-289.
41. Sudlow M, Thomson R, Kenny RA et al. A community survey of patients with atrial fibrillation: associated disabilities and treatment preferences. Br J Gen Pract 1998;48:1775-1778.
42. Levy S, Maarek M, Coumel P et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 1999;99: 3028-3035.
43. Le Heuzey JY, Paziaud O, Piot O et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J 2004;147: 121-126.
44. Leizorovicz A, Guenoun M, Le Heuzey JY et al. The FALSTAF study group. How dose age influence the prescribing of antithrombotic therapy for ambulatory patients with permanent atrial fibrillation? J Am Coll Cardiol 2004;43(Suppl. 1):A135-A136.
45. Hylek EM, Go AS, Chang Y et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-1026.
46. Lip GY. Thromboprophylaxis for atrial fibrillation. Lancet 1999;353: 1620-1621.
47. Wyse DG, Gersh BJ. Atrial fibrillation: a perspective: thinking inside and outside the box. Circulation 2004;109:3089-3095.
48. Protheroe J, Fahey T, Montgomery AA et al. The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ 2000;320:1380-1384.
49. Howitt A, Armstrong D. Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. BMJ 1999; 318:1324-1327.
50. Devereaux PJ, Anderson DR, Gardner MJ et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 2001; 323:1218-1222.
51. Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833.